Key Points {#d30e193}
==========

Prevention of adverse drug events such as falls, fractures and hospitalisations are clinically important outcomes in people aged 65 years and older.Potentially inappropriate medicines (PIMs) identified by the 2012 Beers criteria showed an increased risk of Fall-related hospitalisations (FRH) and a greater number of primary care visits in people aged ≥65 years living in New Zealand.On a population level, Beers criteria can be a useful screening tool to guide prescribing in older people.

Introduction {#Sec1}
============

Prevention of adverse drug events (ADEs) including falls, fractures and hospitalisations are important clinical outcomes in people aged 65 years and older. Polypharmacy (concomitant use of five or more medicines) is an indicator for potentially inappropriate medicine use and has been associated with adverse clinical outcomes in older people \[[@CR1]\]. Identifying exposures to potentially inappropriate medicines (PIMs) that can lead to ADEs can be examined by the use of criterion-based explicit screening tools \[[@CR2], [@CR3]\].

Beers criteria are a universally accepted explicit tool for screening for PIMs in older people \[[@CR2]\]. The Beers criteria have been updated since it was first developed in 1991, and applied in various settings including residential care facilities, acute care and ambulatory care to identify high-risk prescribing in older adults \[[@CR2], [@CR4]--[@CR6]\]. Exposure to PIMs determined by the Beers criteria has shown to be associated with an increased risk of mortality, functional impairment, hospitalisations, delirium, falls, fractures and adverse drug events \[[@CR7]--[@CR10]\]. On the contrary, studies have disaffirmed findings of adverse outcomes to exposure to PIMs listed in the Beers criteria \[[@CR11], [@CR12]\]. Despite recognition of the aforementioned limitations associated with Beers criteria, including not considering drug--drug interactions, dose and duration (overtreatment) and partial applicability internationally (prescribing patterns and drug availability), it still remains one of the widely accepted criterion-based tools for identifying high-risk prescribing in older people.

Corresponding to global trends, the New Zealand population is aging and the total population will comprise of approximately 22--30 % of people aged 65 years and older by 2061 \[[@CR13]\]. Prior studies have shown that a high proportion of older people are prescribed multiple medicines, increasing the risk of exposure to PIMs and potentially leading to ADEs and consequently an increase in healthcare expenditure \[[@CR9], [@CR14]\]. These studies have examined PIMs use in older people; however, outcomes data at a population level is limited \[[@CR15]\]. Hence, the primary objective of this population-level study was to examine the risk of fall-related hospitalisations and primary care visits associated with PIMs use in people aged 65 years and older in New Zealand.

Design and Methods {#Sec2}
==================

Approval to conduct this study was obtained by the Human Ethics Committee at the University of Otago, New Zealand, ethical approval number 12/147.

Study Population and Data Source {#Sec3}
--------------------------------

Anonymous data on all older individuals aged 65 years and above who were dispensed at least one prescription medicine between January 1, 2011 through to December 31, 2011 were identified from the Pharmaceutical Claims Data Mart (Pharms) dataset. The prescriptions data for 559,625 individuals representing approximately 98 % of the total population of older New Zealanders was extracted. For these individuals, demographic information such as sex, date of birth and ethnicity, and prescription details such as date of dispensing, medicine name, medicine dose, dosing frequency and quantity supplied were extracted. The diagnoses were coded using the International Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM). The diagnostic information for 180,978 out of the 559,625 individuals was either missing or unknown.

The following extracts were obtained from the Ministry of Health to undertake this study:Pharms extract files for 2011 contained information on sex, date of birth, medicine, daily dose, frequency, quantity, prioritised ethnicity and District Health Board (DHB) of domicile.National Minimum Data set (2007--2011): information on hospitalisations, event start date (2012), event end date (2012), diagnosis code (ICD-10), accident codes (ICD-10), and procedure codes (ICD-10).General Practitioner (primary care) visits (2012): date of visit/s.

Pharms is used by the Pharmaceutical Management Agency (PHARMAC) and the Ministry of Health of New Zealand to administer payment to pharmacists for dispensing medicines, as well as to assist PHARMAC in its management of the national medicines budget. Pharms extracts are supplied by the Ministry of Health with individual-level prescription data with an encrypted National Health Index (NHI) code which enables individual records to be linked between the various national health data collections whilst still protecting the identity of the individuals. The encryption is an algorithm of the actual NHI. There is only a unique encrypted version of each NHI, which is never changed, allowing linking of new data with datasets previously extracted.

Potentially Inappropriate Medicines (PIMs) Exposure {#Sec4}
---------------------------------------------------

The updated Beers 2012 criteria were used to identify PIMs, both independent of diagnosis and taking diagnosis or dose into consideration. If an individual was dispensed one or more medicine for any duration, at any given time, the individual was said to have an exposure to PIMs. For this study, criterions related to identifying PIMs in lower urinary tract infections and peptic ulcer diseases were modified. To categorise medicines inappropriate for use in individuals with lower urinary tract symptoms and benign prostatic hyperplasia (BPH), only BPH was used as a diagnosis rather than both the symptoms. Additionally, ICD-10 codes for peptic and gastrojejunal ulcers were included with history of gastric or duodenal ulcers.

Chronic Disease Score {#Sec5}
---------------------

Chronic Disease Score (CDS) is a risk-adjustment metric established on patient demographics (age and sex) and account of dispensed medicines \[[@CR16]\]. The CDS was used to compute scores for comorbidities as diagnostic information was unavailable for approximately 33.7 % of the study population. The CDS was included as a covariate in the regression model.

Polypharmacy {#Sec6}
------------

Polypharmacy in individuals was identified as the use of more than five medicines dispensed concurrently for more than or equal to a period of 90 days.

Assessing Clinical Outcomes (Falls-Related Hospitalisation \[FRH\] and Primary Care Visits) {#Sec7}
-------------------------------------------------------------------------------------------

Anonymous linkages via encrypted NHI numbers were used to match prescription data with FRH and primary care visits data between January 1, 2012 and December 31, 2012.

Statistical Analyses {#Sec8}
--------------------

Means and standard deviations were reported for age and number of medicines in the study population. Proportions were reported for sex and ethnicity. The frequency of primary care visits and FRH were found to be over-dispersed with the variance exceeding the mean. The Pearson goodness-of-fit tests confirmed the distribution of primary care visits and falls significantly differed for a Poisson distribution, *p* value of \<0.001 (Prob \> *χ*^2^ \[537,385\]). Hence, a negative binomial regression was used to model the frequency of primary care visits and FRH. Covariates including age, sex, chronic disease scores were common to all regression models. These covariates have been previously shown to be associated with falls and adverse outcomes in older people \[[@CR3]\]. The goodness-of-fit for negative binomial regression models of FRH and primary care visits was analysed. The McFadden's adjusted *R*^2^ for FRH and primary care visits were 0.074 and 0.023, respectively. The maximum likelihood (Cox-Snell) *R*^2^ for FRH and primary care visits were 0.010 and 0.114, respectively. All statistical analyses were conducted using Stata^®^ Corp Release 12. A *p* \< 0.05 was regarded as statistically significant.

Results {#Sec9}
=======

A total of 537,387 individuals 65 years and older were included in the study, of which 54.9 % were females with a mean age of 74.7 years (±7.6). The prevalence of PIMs dispensed was 40.39 % with 78.5 % of individuals dispensed at least one PIM and 21.5 % dispensed two or more PIMs in 2011. The most common PIMs dispensed to the study population were diclofenac (6.0 %) and amitriptyline (4.9 %), followed by ibuprofen (4.6 %), zopiclone (3.2 %) and naproxen (3.0 %). The mean number of medicines dispensed was 5.6 (±3.9) (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the study population (*n* = 537,387)CharacteristicValuePIMs exposure\
OR (95 % CI)Age (mean ± SD)74.72 ± 7.60Age (years) 65--74^a^55.10 %1 75--8432.10 %1.24 (1.23--1.26) ≥8512.80 %1.42 (1.39--1.44)Female sex54.91 %0.88 (0.87--0.89)Ethnicity European^a^79.11 %1 Māori4.70 %0.85 (0.82--0.87) Asian3.76 %0.49 (0.47--0.51) Pacific2.64 %0.63 (0.61--0.65) MELAA0.30 %0.65 (0.53--0.81) Others/unknown9.49 %0.72 (0.70--0.73)Individuals exposed to PIMs ≥140.39 %Mean total number of dispensed medicines5.64 ± 3.91Chronic Disease Score (CDS)6.04 ± 4.971.06 (1.06--1.06)Individuals exposed to polypharmacy33.20 %2.23 (2.21--2.26)Individuals admitted with falls (6 months after study period)2.75 %1.54 (1.49--1.60)GP visits (12 months after study period)64.66 %1.25 (1.24--1.27)*CI* confidence interval, *GP* general practitioner, *MELAA* Middle Eastern/Latin American/African, *OR* odds ratio, *PIMs* potentially inappropriate medicine^a^Reference category

The events (FRH) data for 2012 showed that 2.75 % (14,804) of these individuals had had a FRH in 2012. Of these individuals, 50.8 % (7525/14,804) had an exposure to at least one PIM in 2011. Similarly, data for primary care visits (2012) was matched for all individuals (*n* = 537,387) showing that 64.7 % (*n* = 347,452) of individuals visited their general practitioner one or more times during 2012. Of these individuals, 40.5 % (140,720/347,452) had potentially been exposed to at least one PIM in 2011.

On univariate analysis, PIMs exposure, defined as a categorical variable, was lower in males than in females (odds ratio \[OR\] 0.88; 95 % CI 0.87--0.89) and was greater in Europeans (OR 1.39; 95 % CI 1.37--1.42) in comparison with any other ethnic group. Approximately 30.90 % of individuals were exposed to polypharmacy (OR 2.23; 95 % CI 2.21--2.26).

Table [2](#Tab2){ref-type="table"} summarises the negative binomial regression models used to demonstrate associations of FRH and primary care visits after adjusting for age, sex, CDS scores, and exposure to PIMs. Exposure to PIMs was included in these models as a covariate. Demographic predictors such as female sex (incidence rate ratio \[IRR\] 1.27; 95 % CI 1.20--1.34) and age ≥85 years (IRR 7.27; 95 % CI 6.78--7.79) were significant predictors of FRH. Individuals having an increased chronic disease score also predicted an increased risk of FRH and primary care visits.Table 2Regression models demonstrating the associations with exposure to PIMs predicting the risks of Fall-related hospitalisations and primary care visitsNBR model\
IRR (95 % CI)FRHPrimary care visitsAge (years) 65--74^a^11 75--842.90 (2.72--3.11)1.15 (1.15--1.16) ≥857.27 (6.79--7.80)1.30 (1.30--1.31)Male^a^11Female1.27 (1.20--1.34)1.06 (1.06--1.07)Chronic Disease Score1.05 (1.05--1.06)1.02 (1.03--1.03)No polypharmacy (0--4)^a^11Polypharmacy ≥51.41 (1.33--1.50)1.14 (1.13--1.15)No exposure to PIMs^a^11Exposure to PIMs ≥11.45 (1.37--1.52)1.15 (1.15--1.16)*CI* confidence interval, *FRH* Fall-related hospitalisations, *IRR* incidence rate ratio, *NBR* negative binomial regression, *PIMS* potentially inappropriate medicine^a^Reference category

Exposure to one or more PIMs showed an increased risk of FRH (IRR 1.45; 95 % CI 1.37--1.53) and primary care visits (IRR 1.15; 95 % CI 1.15--1.16). Individuals exposed to polypharmacy had an IRR of 1.41 (95 % CI 1.37--1.52) for FRH and IRR of 1.14 (95 % CI 1.15--1.16) for primary care visits.

Discussion {#Sec10}
==========

This population-level study of older New Zealanders identified that approximately 41 % of individuals aged 65 years and older were dispensed at least one PIM in 2011 and over 50 % of individuals with FRH in 2012 were exposed to at least one PIM in 2011. Additionally, 40.5 % of individuals with at least one primary care visit in 2012 were also exposed to one PIM in 2011. Age, sex, CDS, polypharmacy and exposure to PIMs were all predictors of FRH and the frequency of primary care visits in 2012. Three of the top five PIMs dispensed were non-steroidal anti-inflammatory drugs and it is well established that these medicines have a potential to increase the risk of cardiovascular, renal and haematological adverse events in older people \[[@CR17], [@CR18]\].

There are limitations to this study. Similar to other global studies using the Beers criteria, not all medicines listed were available in New Zealand or funded by PHARMAC. In addition, only the first twenty diagnoses were accessible from the minimum data set obtained from the Ministry of Health. Additionally, medicines not funded by PHARMAC and over-the-counter medicines not captured by Pharms may have underestimated the exposure to PIMs in this study population. Furthermore, a retrospective study design limits causal relationships between PIMs exposure and adverse outcomes.

Our study showed an increased risk of FRH and primary care visits associated with exposure to PIMs. This result is consistent with findings that have linked exposure to PIMs and polypharmacy to adverse health outcomes \[[@CR10], [@CR19], [@CR20]\]. Klarin et al. \[[@CR10]\] reported that community-dwelling older people exposed to PIMs had an increased risk of hospitalisation. Previous studies have demonstrated the utility of administrative health data to examine appropriateness of prescribing \[[@CR21]--[@CR24]\].

The charge for fully subsidised medicines at the time of this study was NZ\$3, and very few prescriptions would cost more than \$3. Hence, a large proportion of dispensing in this age group was captured by Pharms. Selection bias may have been eliminated given that almost the entire older population of New Zealand is captured in the Pharms dataset. Another major strength was the availability of ICD-10 codes which enabled linkage of prescription, diagnosis and events datasets.

This study is the first in New Zealand to examine the relationship between exposure to PIMs and FRH and primary care visits at a population level. Congruent to the findings from previous research, exposure to PIMs is associated with an increased risk of hospitalisations and poor health outcomes \[[@CR10], [@CR25]--[@CR27]\]. Use of such criteria can enable improved prescribing by flagging alerts into the physician dispensing software or into electronic prescribing software or into decision support systems maintained by healthcare organisations.

Conclusion {#Sec11}
==========

Using the updated Beers 2012 criteria, exposure to PIMs showed an association with FRH and frequency of primary care visits. Age ≥85 years and female sex were identified as significant predictors of FRH and primary care visits. On a population level, Beers criteria may be a useful screening tool to identify high-risk prescribing and reduce adverse outcomes in older people.
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